$ILNS "RECALL-VAX" technology

The RECALL-VAX™ technology invented by Dr. Benjamin Chain, Ph.D., (brother of Daniel Chain) is designed to reduce or eliminate an autoimmune response and to ensure that the antibodies produced by the patient’s immune system only attack the A? protein.  If effective, this technology couldsignificantly reduce the likelihood of side-effects such as those seen with AN-1792, which was discontinued by Elan Corporation in 2002. The company believes that its particular combination of human Aß and bacterial (tetanus toxoid) polypeptides to provide B and T-helper epitopes, respectively, encourages a robust immune response with lessened danger of contamination from potentially harmful human Aß T-cell epitopes. Moreover, by using only very short fragments of the Aß toxin, the immune response is more specific than when using full length or larger pieces of Aß, ensuring that only the toxin and not the amyloid precursor protein is targeted by the antibody.  Based on preliminary studies in non-transgenic mice, the company has identified two drug candidates for further development: RV01 and RV02, which are free end specific for the amino-terminus and carboxyl-terminus, respectively.

Figure 2: RV01 targeting N-terminus of A?